{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:38:03Z","timestamp":1791261483432,"version":"4.1.0"},"reference-count":49,"publisher":"Impact Journals, LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2014,2,15]]},"DOI":"10.18632\/oncotarget.1455","type":"journal-article","created":{"date-parts":[[2015,9,16]],"date-time":"2015-09-16T20:56:42Z","timestamp":1442437002000},"page":"726-739","source":"Crossref","is-referenced-by-count":22,"title":["Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in <i>in vivo<\/i> and <i>in vitro<\/i> models of mantle cell lymphoma"],"prefix":"10.18632","volume":"5","author":[{"given":"Arnau","family":"Montraveta","sequence":"first","affiliation":[{"name":"Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00edlvia","family":"Xargay-Torrent","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"L\u00f3pez-Guerra","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Rosich","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"P\u00e9rez-Gal\u00e1n","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itziar","family":"Salaverria","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Be\u00e0","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana G.","family":"Kalko","sequence":"additional","affiliation":[{"name":"Bioinformatics Core Facility, IDIBAPS, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"de Frias","sequence":"additional","affiliation":[{"name":"Advancell-Advanced In Vitro Cell Technologies S.A., Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Camp\u00e0s","sequence":"additional","affiliation":[{"name":"Advancell-Advanced In Vitro Cell Technologies S.A., Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00ebl","family":"Rou\u00e9","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolors","family":"Colomer","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"},{"name":"Hematopathology Unit, Hospital Cl\u00ednic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2014,1,25]]},"reference":[{"issue":"10","key":"1","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","article-title":"Molecular pathogenesis of mantle cell lymphoma","volume":"122","author":"Campo","year":"2012","journal-title":"J Clin Invest"},{"issue":"13","key":"2","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1158\/1078-0432.CCR-11-3152","article-title":"New strategies in the treatment of mantle cell lymphoma","volume":"18","author":"O'Connor","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"18","key":"3","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2011-04-348367","article-title":"Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma","volume":"118","author":"Dreyling","year":"2011","journal-title":"Blood"},{"issue":"9873","key":"4","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Roller","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s11864-013-0230-z","article-title":"Current and emerging therapies in mantle cell lymphoma","volume":"14","author":"Williams","year":"2013","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"Wiestner","year":"2011","journal-title":"Blood"},{"issue":"6","key":"7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Jedrzejczak","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"8","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1517\/13543781003703694","article-title":"AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies","volume":"19","author":"Bontemps","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"issue":"12","key":"9","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1517\/14656566.9.12.2137","article-title":"Acadesine, an adenosine-regulating agent with the potential for widespread indications","volume":"9","author":"Kingwell","year":"2008","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"10","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1074\/jbc.M605702200","article-title":"Inhibition of hepatic phosphatidylcholine synthesis by 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside is independent of AMP-activated protein kinase activation","volume":"282","author":"Vance","year":"2007","journal-title":"J Biol Chem"},{"issue":"3","key":"11","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/jcb.21466","article-title":"Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase and cyclooxygenase-2 gene expression by 5-aminoimidazole-4-carboxamide riboside is independent of AMP-activated protein kinase","volume":"103","author":"Lin","year":"2008","journal-title":"J Cell Biochem"},{"issue":"4","key":"12","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2337\/diabetes.55.04.06.db05-1178","article-title":"5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside and metformin inhibit hepatic glucose phosphorylation by an AMP-activated protein kinase-independent effect on glucokinase translocation","volume":"55","author":"Hue","year":"2006","journal-title":"Diabetes"},{"issue":"16","key":"13","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1182\/blood-2010-05-283960","article-title":"AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells","volume":"116","author":"Gil","year":"2010","journal-title":"Blood"},{"issue":"16","key":"14","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1016\/j.yexcr.2007.06.020","article-title":"Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells","volume":"313","author":"Schmidmaier","year":"2007","journal-title":"Exp Cell Res"},{"key":"15","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1080\/15257770600890905","article-title":"5 \u2018-Amino-4-imidazolecarboxamide riboside induces apoptosis in human neuroblastoma cells via the mitochondrial pathway","volume":"25","author":"Camici","year":"2006","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"31","key":"16","doi-asserted-by":"crossref","first-page":"12932","DOI":"10.1073\/pnas.0906606106","article-title":"The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis","volume":"106","author":"Mischel","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1476-4598-6-46","article-title":"Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy","volume":"6","author":"Barredo","year":"2007","journal-title":"Mol Cancer"},{"issue":"5","key":"18","first-page":"1562","article-title":"5-Aminoimidazole-4-carboxamide riboside sensitizes T","volume":"6","author":"Lin","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"19","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1158\/0008-5472.CAN-04-3025","article-title":"Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype","volume":"65","author":"Verhoeven","year":"2005","journal-title":"Cancer Res"},{"issue":"2","key":"20","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/sj.leu.2403593","article-title":"Acadesine induces apoptosis in B cells from mantle cell lymphoma and splenic marginal zone lymphoma","volume":"19","author":"Gil","year":"2005","journal-title":"Leukemia"},{"issue":"9","key":"21","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood-2002-07-2339","article-title":"Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes","volume":"101","author":"Gil","year":"2003","journal-title":"Blood"},{"issue":"3","key":"22","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00280-012-2033-5","article-title":"Acadesine for patients with relapsed\/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I\/II study","volume":"71","author":"Campas","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"23","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/blood.V96.6.2219","article-title":"Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures","volume":"96","author":"Jurlander","year":"2000","journal-title":"Blood"},{"issue":"47","key":"24","doi-asserted-by":"crossref","first-page":"39582","DOI":"10.1074\/jbc.M507443200","article-title":"5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase","volume":"280","author":"Singh","year":"2005","journal-title":"J Biol Chem"},{"issue":"6","key":"25","first-page":"1875","article-title":"Anti-growth effect of 1,25-dihydroxyvitamin D3-3-bromoacetate alone or in combination with 5-amino-imidazole-4-carboxamide-1-beta-4-ribofuranoside in pancreatic cancer cells","volume":"30","author":"Ray","year":"2010","journal-title":"Anticancer Res"},{"issue":"3","key":"26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10565-008-9075-9","article-title":"Overexpression of CYP2E1 induces HepG2 cells death by the AMP kinase activator 5'-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR)","volume":"25","author":"Zhuge","year":"2009","journal-title":"Cell Biol Toxicol"},{"issue":"24","key":"27","doi-asserted-by":"crossref","first-page":"6399","DOI":"10.1182\/blood-2011-01-332783","article-title":"Antileukemic effects of AMPK activators on BCR-ABL-expressing cells","volume":"118","author":"Platanias","year":"2011","journal-title":"Blood"},{"issue":"11","key":"28","doi-asserted-by":"crossref","first-page":"e7889","DOI":"10.1371\/journal.pone.0007889","article-title":"Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death","volume":"4","author":"Auberger","year":"2009","journal-title":"PLoS One"},{"issue":"8","key":"29","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood.V94.8.2836.420k35_2836_2843","article-title":"In vitro evaluation of fludarabine in combination with cyclophosphamide and\/or mitoxantrone in B-cell chronic lymphocytic leukemia","volume":"94","author":"Gil","year":"1999","journal-title":"Blood"},{"issue":"4","key":"30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.cell.2011.01.017","article-title":"Amon A: Identification of aneuploidy-selective antiproliferation compounds","volume":"144","author":"Siegel","year":"2011","journal-title":"Cell"},{"issue":"26","key":"31","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1038\/onc.2012.339","article-title":"Aneuploid human colonic epithelial cells are sensitive to AICAR-induced growth inhibition through EGFR degradation","volume":"32","author":"Shay","year":"2013","journal-title":"Oncogene"},{"issue":"21","key":"32","doi-asserted-by":"crossref","first-page":"6907","DOI":"10.1158\/1078-0432.CCR-08-0388","article-title":"Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling","volume":"14","author":"Colomer","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"1","key":"33","doi-asserted-by":"crossref","first-page":"e52852","DOI":"10.1371\/journal.pone.0052852","article-title":"Aminoimidazole carboxamide ribonucleotide (AICAR) inhibits the growth of retinoblastoma in vivo by decreasing angiogenesis and inducing apoptosis","volume":"8","author":"Vavvas","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"34","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3324\/haematol.2011.041392","article-title":"Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma","volume":"96","author":"Drach","year":"2011","journal-title":"Haematologica"},{"issue":"4","key":"35","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","article-title":"Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study","volume":"12","author":"Witzig","year":"2011","journal-title":"Lancet Oncol"},{"issue":"7","key":"36","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Champlin","year":"2012","journal-title":"Lancet Oncol"},{"issue":"1","key":"37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1158\/1078-0432.CCR-10-1292","article-title":"Interindividual variability of response to rituximab: from biological origins to individualized therapies","volume":"17","author":"Hallek","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"21","key":"38","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1056\/NEJMct1114348","article-title":"Anti-CD20 antibody therapy for B-cell lymphomas","volume":"366","author":"Maloney","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"39","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood.V98.9.2771","article-title":"Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species","volume":"98","author":"Montserrat","year":"2001","journal-title":"Blood"},{"issue":"2","key":"40","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.gene.2012.09.118","article-title":"Analysis of microRNA expression profile induced by AICAR in mouse hepatocytes","volume":"512","author":"Zhang","year":"2013","journal-title":"Gene"},{"issue":"25","key":"41","doi-asserted-by":"crossref","first-page":"16971","DOI":"10.1074\/jbc.M708459200","article-title":"Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling","volume":"283","author":"Cragg","year":"2008","journal-title":"J Biol Chem"},{"issue":"2","key":"42","doi-asserted-by":"crossref","first-page":"e16596","DOI":"10.1371\/journal.pone.0016596","article-title":"Antibodies against CD20 or B-cell receptor induce similar transcription patterns in human lymphoma cell lines","volume":"6","author":"Burtscher","year":"2011","journal-title":"PLoS One"},{"issue":"25","key":"43","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1038\/sj.onc.1210365","article-title":"Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo\/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions","volume":"26","author":"Bonavida","year":"2007","journal-title":"Oncogene"},{"issue":"10","key":"44","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1182\/blood-2006-04-015305","article-title":"Prognostic significance of metallothionein in B-cell lymphomas","volume":"108","author":"Ralfkiaer","year":"2006","journal-title":"Blood"},{"issue":"14","key":"45","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1158\/1078-0432.CCR-11-0479","article-title":"Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma","volume":"17","author":"Law","year":"2011","journal-title":"Clin Cancer Res"},{"key":"46","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Talalay","year":"1984","journal-title":"Adv Enzyme Regul"},{"issue":"2","key":"47","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2144\/03342mt01","article-title":"TM4: a free, open-source system for microarray data management and analysis","volume":"34","author":"Kostukovich","year":"2003","journal-title":"Biotechniques"},{"key":"48","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.febslet.2004.07.055","article-title":"Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments","volume":"573","author":"Herzyk","year":"2004","journal-title":"FEBS Lett"},{"issue":"4","key":"49","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1182\/blood-2010-04-278853","article-title":"The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP\/Grp78","volume":"117","author":"Colomer","year":"2011","journal-title":"Blood"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.1455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T14:06:20Z","timestamp":1594821980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.1455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,25]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,2,15]]}},"alternative-id":["1455","24519895"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.1455","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,25]]}}}